

## Information about proposed Board of Directors Annual General Meeting 2017

---

### *Proposal for re-election of the current members of the board of directors:*

#### **Håkan Björklund**

Chairman

Born 1956. Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016.

*Other appointments:* Industry Executive at Avista Capital Partners. Member of the Board of Directors of Bonesupport, Acino and Trimb.

*Previous appointments:* CEO and President of Nycomed. Extensive international background in the life science industry, from both R&D and sales and marketing. Håkan has served as a Member of the Board of Directors of several international life science companies including Alere, Coloplast, Danisco, and Lundbeck. Between 2001 and 2007, Håkan Björklund also served as member of the Board of Directors for Biovitrum.

*Shares:* 15,800

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Håkan Björklund is proposed for re-election both as member of the board of directors and re-election as chairman of the board.

#### **Annette Clancy**

Born 1954. BSc Hons Pharmacology from Bath University UK. Board member since 2014.

*Other appointments:* Non executive Chairman of the Board of two European biotechnology companies Enyo SA and Lysogene SA. Member of the Board of Directors of Obseva SA, a US publically traded Company. Senior European Advisor to the Biopharmaceutical Team of Frazier Healthcare Ventures, for whom she provides strategic advice on both new and existing investments. Ms. Clancy has over 30 years of experience in the Pharmaceutical/Biopharm Industry, working in a variety of functions (R&D, Commercial, Worldwide Business Development) in the US and UK.

*Previous appointments:* Head of Transactions and Alliance Management at GlaxoSmithKline (GSK) where she was responsible for executing major transactions ranging from early drug discovery partnerships, to global commercial alliances as well as Mergers and Acquisitions until her retirement in 2008. Non-Executive Board Director of Silence Therapeutics plc. (2008-2012) and Clavis Pharma (2010-2013) and Chair of the Board of Directors for Genable Therapeutics (2013-2016).

*Shares:* 3,414

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Matthew Gantz**

Born 1965. BA Princeton University and MBA from Harvard Business School. Board member since 2012.

*Other appointments:* Member of the Life Science Pennsylvania Industry Board.

*Previous appointments:* Executive Vice President of BTG. Founder and CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., VP Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division.

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Theresa Heggie**

Born 1960. BSc. from Cornell University, Ithaca, NY, USA. Board member since 2016.

*Previous appointments:* Chief Strategy & Marketing Officer, Bupa, various senior commercial positions at Shire Human Genetic Therapies, formerly TKT, including the roles of Vice President & General Manager, EMEA, Chief Executive Officer, Jerini AG (a Shire acquisition) and Senior Vice President Global Commercial Operations. Vice President Marketing, Vice President Anaesthesia & Critical Care, Europe, and Vice President, Global Marketing Anaesthesia & Critical Care with Baxter – and formerly Ohmeda PPD.

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Lennart Johansson**

Born 1955. MBA from Stockholm School of Economics. Board member since 2010.

*Other appointments:* Member of the management team and Senior Advisor at Patricia Industries - a part of Investor AB. Chairman of the Board of Vectura AB, board member of HI3G and deputy board member of Mölnlycke.

*Previous appointments:* CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB and Gambro Holding AB.

*Shares:* 20,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Helena Saxon**

Born 1970. MSc from Stockholm School of Economics. Board member since 2011.

*Other appointments:* CFO at Investor AB. Board member of SEB.

*Previous appointments:* CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

*Shares:* 15,500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Hans GCP Schikan**

Born 1958. PharmD, Utrecht University. Board member since 2011.

*Other appointments:* Chairman of the Board of Directors of Asceneuron, Switzerland, Interna Technologies, The Netherlands and Complix, Belgium. Member of the Board of Directors of Hansa Medical and Wilson Therapeutics, Sweden, Therachon, Switzerland as well as in the Dutch Top Sector Life Sciences & Health, The Netherlands. Advisor to various organisations in Life Sciences & Health.

*Previous appointments:* CEO of Prosensa, Director of the Supervisory Board of Prosensa, Board member of Top Institute Pharma, Chairman of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Various senior management positions within previous Organon and Genzyme.

*Shares:* 4,000

Independent in relation to the company and its management and in relation to the company's principal shareholders.